| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 09/19/2002 | WO2001097779A3 Improved injectable dispersions of propofol |
| 09/19/2002 | WO2001083521A3 Reductive alkylation process on glycopeptides |
| 09/19/2002 | WO2001080902A3 A particulate complex for administering nucleic acid into a cell |
| 09/19/2002 | WO2001060890A3 Method for preparing functionalised polyalkylenimines, composition containing same and uses thereof |
| 09/19/2002 | WO1997046589A3 Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods |
| 09/19/2002 | US20020133235 Cell-culture and polymer constructs |
| 09/19/2002 | US20020133019 Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and vivo imaging and prevention of amyloid deposition |
| 09/19/2002 | US20020133003 Method of preparing and uses of cucurbituril devices |
| 09/19/2002 | US20020133001 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease |
| 09/19/2002 | US20020132982 Complexing antihemophila factor in fluid; obtain antihemophila protein, adjust protein conformation, bind to stabilizer, monitor activity |
| 09/19/2002 | US20020132979 Monoclonal antibody for use in the diagnosis, prevention and treatment of tumors |
| 09/19/2002 | US20020132852 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use |
| 09/19/2002 | US20020132850 Multilayer tablet for administering a fixed combination of tramadol and diclofenac |
| 09/19/2002 | US20020132827 Using full D1 dopamine receptor agonists in an intermittent dosing protocol with a short, but essential, "off-period." |
| 09/19/2002 | US20020132819 Phosphoryl derivatives of purines; treatment of bone related disorders and cancer |
| 09/19/2002 | US20020132805 Containing about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid, including salts such as disodium EDTA; especially the antihistamines loratadine, descarboethoxyloratadine, and azatadine |
| 09/19/2002 | US20020132787 Compositions and methods for nucleic acid delivery to the lung |
| 09/19/2002 | US20020132780 Gelatin, cartilage, aminosugars, glycosaminoglycans, dimethyl sulfone or precursors, or S-adenosylmethionine; sweetening agent; and water; treating joint and bone dysfunction and inflammation. |
| 09/19/2002 | US20020132777 Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients |
| 09/19/2002 | US20020132771 Binding agent that specifically binds to both soluble and tumor-bound tumor- associated MUC-1 and that is effective in therapeutically treating a mammal having a tumor that expresses a tumor- associated MUC-1. |
| 09/19/2002 | US20020132769 Comprising a soluble adenoviral receptor domain, a trimerization domain, and a targeting ligand domain; using molecule to treat a disease, such as cancer, with adenoviral gene therapy; side effect reduction |
| 09/19/2002 | US20020132766 Design, preparation, and properties of antibacterial beta-peptides |
| 09/19/2002 | US20020132312 Removing gases from preferential zones; obtain cells, induce cells to float, harvest cells, crosslink, cells, remove gas |
| 09/19/2002 | US20020132030 Edible microbiocide of .05-1.0% alkyl paraben, and .1-.2% benzoic and sorbic acids salts |
| 09/19/2002 | US20020132018 Use of non-alkalized cocoa solids in a drink |
| 09/19/2002 | US20020132015 Compositions and methods for high sorption of skin materials and delivery of sulfur |
| 09/19/2002 | US20020132011 Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
| 09/19/2002 | US20020132009 Entacapone, nitecapone, or salts thereof and croscarmellose sodium to increase the release rate; catechol-O-methyl transferase inhibitors |
| 09/19/2002 | US20020132006 Odor-masking coating for a pharmaceutical preparation |
| 09/19/2002 | US20020131999 Using stearic acid or zinc stearate as lubricant |
| 09/19/2002 | US20020131998 Rapidly dissolving dosage form and process for making same |
| 09/19/2002 | US20020131995 Drug delivery system comprising delivery vehicle having low molecular weight hyaluronan ligand with affinity for CD44 receptors |
| 09/19/2002 | US20020131994 Comprising active substance in combination with a biopolymer; transdermal delivery of active substance |
| 09/19/2002 | US20020131993 Gel, ointment, solution, suspension or film containing mixture of nicotine and an uncrosslinked, water-insoluble vinypyrrolidone copolymer with hydrophobic comonomer for sustained transdermal delivery of nicotine; smoking-cessation |
| 09/19/2002 | US20020131988 Provides flexibility in adjusting release of medicament; faster onset of release can be provided along with a long-term sustained-release |
| 09/19/2002 | US20020131984 Immunogenic conjugates comprising a group B meningococcal porin and an H. influenzae polysaccharide |
| 09/19/2002 | US20020131982 For use for preparing vaccines and immune stimulating compositions for oral, nasal, urogenital and/or rectal administration |
| 09/19/2002 | US20020131980 Comprises an immunizing amount of Mycoplasma hyopneumoniae bacterin, an adjuvant mixture comprising an acrylic acid polymer, a metabolizable oil, a polyoxyethylene polypropylene block copolymer, and an pharmaceutically acceptable carrier |
| 09/19/2002 | US20020131973 A target cell specific antibody, an enzyme that converts a non-cytotoxic substance such as a prodrug into its cytotoxic form inside the target cell, enzyme requires a factor that is not present in vascular system but inside target cell |
| 09/19/2002 | US20020131965 Conjugate of a bioactive agent covalently attached to a transport polymer, having guanidino or amidino side chains, such as an arginine-containing polypeptide |
| 09/19/2002 | US20020131952 Biodegradation, time-release agents, drug delivery |
| 09/19/2002 | US20020131951 Biodegradable poly(beta-amino esters) and uses thereof |
| 09/19/2002 | DE10112651A1 Inhomogene Kieselsäuren als Trägermaterial Inhomogeneous silicas as carrier material |
| 09/19/2002 | DE10111843A1 Verbindungen zur Behandlung von inflammatorischen Erkrankungen Compounds for the treatment of inflammatory disorders |
| 09/19/2002 | DE10110953A1 Transdermales therapeutisches System zur Verabreichung von partiellen Dopamin-D2-Agonisten Transdermal therapeutic system for administration of partial dopamine-D2 agonists |
| 09/19/2002 | DE10108857A1 Bioaktive und biokompatible Konjugate mit magnetischen Eigenschaften und Verfahren zu deren Herstellung Bioactive and biocompatible conjugates with magnetic properties and methods for their preparation |
| 09/19/2002 | CA2702192A1 Igf antagonist peptides |
| 09/19/2002 | CA2470152A1 Transfection complexes comprising a novel peptide as cell surface receptor binding component |
| 09/19/2002 | CA2441854A1 Composition for rectal delivery of an oxazolidinone antibacterial drug |
| 09/19/2002 | CA2440973A1 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour |
| 09/19/2002 | CA2440935A1 Micellar drug delivery vehicles and precursors thereto and uses thereof |
| 09/19/2002 | CA2440773A1 Novel mhc molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of mhc molecules |
| 09/19/2002 | CA2440641A1 Chronotherapeutic dosage forms containing glucocorticosteroid |
| 09/19/2002 | CA2440412A1 Taste masked liquid pharmaceutical compositions |
| 09/19/2002 | CA2440225A1 Taxane prodrugs |
| 09/19/2002 | CA2440209A1 Topical patch preparation containing a delayed-type hypersensitivity inducer and methods for using the same |
| 09/19/2002 | CA2440208A1 Tumour targeting prodrugs activated by metallo matrixproteinases |
| 09/19/2002 | CA2439953A1 Stabilized therapeutic and imaging agents |
| 09/19/2002 | CA2439897A1 Enzyme-activated cytostatic conjugates with integrin ligands |
| 09/19/2002 | CA2439774A1 Compositions and methods for non-insulin glucose uptake |
| 09/19/2002 | CA2438401A1 Pharmaceutical composition |
| 09/19/2002 | CA2438164A1 Use of preparations containing selenite or selenate |
| 09/19/2002 | CA2437746A1 Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein |
| 09/19/2002 | CA2433353A1 Crystals of whole antibodies and fragments thereof and methods for making and using them |
| 09/19/2002 | CA2341998A1 Anti-emetic, anti-motion sustained release drug delivery system, |
| 09/18/2002 | EP1241258A2 Stem cell factor |
| 09/18/2002 | EP1241134A2 Inhomogeneous silica as support |
| 09/18/2002 | EP1241113A1 Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein |
| 09/18/2002 | EP1240897A1 Pharmaceutical tablet and process for making thereof |
| 09/18/2002 | EP1240396A1 A ventilating device for ventilating through a ridge |
| 09/18/2002 | EP1240343A2 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression |
| 09/18/2002 | EP1240337A2 Methods and compositions for prolonging elimination half-times of bioactive compounds |
| 09/18/2002 | EP1240327A2 Interferon-like molecules and uses thereof |
| 09/18/2002 | EP1240285A1 Stabilisation of pigments and polyunsaturated oils and oil concentrates |
| 09/18/2002 | EP1240230A1 Swelling and deswelling polymer blends |
| 09/18/2002 | EP1240215A1 Method for the emulsion polymerisation of olefins |
| 09/18/2002 | EP1240212A1 Crosslinked copolymers based on non-crosslinked polycarboxylic copolymers |
| 09/18/2002 | EP1240190A1 Uses of transport proteins for controlling cell cycle |
| 09/18/2002 | EP1239923A2 Stabilized veterinary compositions comprising more than one antiviral agent |
| 09/18/2002 | EP1239887A1 Cobalamin conjugates useful as imaging and therapeutic agents |
| 09/18/2002 | EP1239884A2 Methods for preparing pharmaceutical formulations |
| 09/18/2002 | EP1239874A1 Method of diagnosing, monitoring, staging, imaging and treating prostate cancer |
| 09/18/2002 | EP1239872A2 Enzyme treatment for infection |
| 09/18/2002 | EP1239857A1 Dual-release compositions of a cyclooxygenase-2- inhibitor |
| 09/18/2002 | EP1239856A1 Sustained-release formulation of a cyclooxygenase-2 inhibitor |
| 09/18/2002 | EP1239849A2 Pharmaceutical formulations comprising resveratrol and use thereof |
| 09/18/2002 | EP1239846A2 Transdermal administration of phenylpropanolamine |
| 09/18/2002 | EP1239845A2 Hydroxide-releasing agents as skin permeation enhancers |
| 09/18/2002 | EP1239844A1 Process for producing nanometer particles by fluid bed spray-drying |
| 09/18/2002 | EP1239841A1 Pharmaceutical formulations comprising sodium amoxycilline and potassium clavulanate |
| 09/18/2002 | EP1239839A2 Hydrogel-driven layered drug dosage form comprising sertraline |
| 09/18/2002 | EP1239837A2 Direct compression polymer tablet core |
| 09/18/2002 | EP1239836A1 Colloidal suspension of submicronic particles as vectors for active principles and method for preparing same |
| 09/18/2002 | EP1239835A1 Pharmaceutical compositions providing enhanced drug concentrations |
| 09/18/2002 | EP1239832A2 Suspension comprising oxcarbazepine |
| 09/18/2002 | EP1239831A1 Improved pharmaceutical compositions for poorly soluble drugs |
| 09/18/2002 | EP1239829A1 Devices for the delivery of drugs having antiprogestinic properties |
| 09/18/2002 | EP1239826A2 Cosmetic and/or pharmaceutical preparations |
| 09/18/2002 | EP1239824A2 Scar treatment composition comprising a silicone mixture |
| 09/18/2002 | EP0981748A4 Signal enhancement of bispecific antibody-polymer probe for immunoassay use |